Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 18, 2015; 7(11): 1553-1561
Published online Jun 18, 2015. doi: 10.4254/wjh.v7.i11.1553
Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein
Su Jong Yu, Yoon Jun Kim
Su Jong Yu, Yoon Jun Kim, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 110-744, South Korea
Author contributions: Kim YJ designed research; Yu SJ performed literature search and wrote the paper.
Conflict-of-interest: The authors have no commercial, proprietary or financial interest in the products or companies described in this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yoon Jun Kim, MD, Professor, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, South Korea. yoonjun@snu.ac.kr
Telephone: +82-2-20723081 Fax: +82-2-7436701
Received: September 23, 2014
Peer-review started: September 23, 2014
First decision: November 27, 2014
Revised: March 16, 2015
Accepted: April 10, 2015
Article in press: April 14, 2015
Published online: June 18, 2015
Core Tip

Core tip: Given the modest survival gain and the limitation of sorafenib, such as resistance and tolerability, there are still clinical unmet needs in the management of patients with hepatocellular carcinoma (HCC) accompanying portal vein tumor thrombosis (PVTT). Surgical resection-based multimodal treatments including liver transplantation and transarterial chemoembolization-based appropriate combination strategies for resectable HCC accompanying PVTT may improve overall survival in these patients.